🏢 官网IRALKSDoubao · 实盘不做把握 9/10不做原因:不是事件
北京时间·🕒 发布 04:00:00(美东 10-20 16:00)·⟳ 抓取 04:06:46回填·⚡ 决策 10-21 04:57:06·6.6 天前
Alkermes公告将于11月3日召开三季度业绩电话会，仅为日程通知无任何业绩数据
该IR稿是典型的earnings call save-the-date，只通知开会时间和接入方式，没有任何业绩、指引、订单或管线增量信息；距离真正财报日(11月3日)尚有两周，无事件驱动edge，无方向可交易。
📄 原文ALKS↗ 原文
Alkermes to Report Third Quarter Financial Results on November 3, 2026
DUBLIN --(BUSINESS WIRE)--Oct. 20, 2026-- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentat…
不做 Alkermes plc（ALKS.US）
纯财报电话会日程预告，无任何业绩、指引或管线增量事实，方向不明、无edge；真正催化在2026-11-03财报发布，届时再研判。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Alkermes仅宣布将于11月3日讨论Q3业绩，稿件不含任何数字或指引，属程序性日程通知，对股价无新增信息，不做。
主要风险
- 真正催化在11月3日财报本身，当前提前进场等于无信息依据地裸博财报，方向不明。
先例如何影响了这次决策
对本次决策的影响:因无事件内容，不援引任何先例也不设定幅度；待11月3日实际财报再研究。
方向:无可对照先例；财报电话会日程预告本身不产生方向信息
涨幅量级:不适用
形态:不适用
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 12 ms
{"result": "search_processed_events:agent query=`alkermes third quarter 2026 financial results conference call november 3 2026 | alks q3 2026 earnings date announcement`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"}
原文全文
展开原文 · 1,778 字
DUBLIN
--(BUSINESS WIRE)--Oct. 20, 2026--
Alkermes plc
(Nasdaq: ALKS) will host a conference call and webcast presentation at
8:00 a.m. ET
(
1:00 p.m. GMT
) on
Tuesday, November 3, 2026
to discuss the company’s third quarter financial results.
The webcast player and accompanying slides may be accessed on the Investors section of Alkermes’ website at
www.alkermes.com
. The conference call may be accessed by dialing +1 877 407 2988 for
U.S
. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes’ website.
About Alkermes plc
Alkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Alkermes’ pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes’ website at
www.alkermes.com
.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20261020456820/en/
Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402
Source: Alkermes plc
--(BUSINESS WIRE)--Oct. 20, 2026--
Alkermes plc
(Nasdaq: ALKS) will host a conference call and webcast presentation at
8:00 a.m. ET
(
1:00 p.m. GMT
) on
Tuesday, November 3, 2026
to discuss the company’s third quarter financial results.
The webcast player and accompanying slides may be accessed on the Investors section of Alkermes’ website at
www.alkermes.com
. The conference call may be accessed by dialing +1 877 407 2988 for
U.S
. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes’ website.
About Alkermes plc
Alkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Alkermes’ pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes’ website at
www.alkermes.com
.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20261020456820/en/
Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402
Source: Alkermes plc
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
b85fd6cb74· 2026-10-21 04:57 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前